X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs STRIDES PHARMA SCIENCE - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS STRIDES PHARMA SCIENCE NOVARTIS/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 424.9 19.6 2,164.3% View Chart
P/BV x 30.0 0.8 3,548.3% View Chart
Dividend Yield % 1.5 0.6 265.1%  

Financials

 NOVARTIS   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    NOVARTIS
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
NOVARTIS/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs7581,147 66.1%   
Low Rs579642 90.2%   
Sales per share (Unadj.) Rs228.4317.2 72.0%  
Earnings per share (Unadj.) Rs31.77.8 404.6%  
Cash flow per share (Unadj.) Rs32.825.1 130.8%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.50.2 669.0%  
Book value per share (Unadj.) Rs297.1274.3 108.3%  
Shares outstanding (eoy) m24.6989.50 27.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.92.8 103.8%   
Avg P/E ratio x21.1114.0 18.5%  
P/CF ratio (eoy) x20.435.7 57.2%  
Price / Book Value ratio x2.23.3 69.0%  
Dividend payout %31.525.5 123.6%   
Avg Mkt Cap Rs m16,50580,058 20.6%   
No. of employees `0000.72.5 26.6%   
Total wages/salary Rs m1,4454,341 33.3%   
Avg. sales/employee Rs Th8,441.311,325.8 74.5%   
Avg. wages/employee Rs Th2,163.61,731.4 125.0%   
Avg. net profit/employee Rs Th1,173.1280.1 418.9%   
INCOME DATA
Net Sales Rs m5,63928,394 19.9%  
Other income Rs m1,718941 182.7%   
Total revenues Rs m7,35729,334 25.1%   
Gross profit Rs m-633,965 -1.6%  
Depreciation Rs m251,540 1.6%   
Interest Rs m551,962 2.8%   
Profit before tax Rs m1,5751,403 112.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m79297 813.6%   
Profit after tax Rs m784702 111.6%  
Gross profit margin %-1.114.0 -7.9%  
Effective tax rate %50.36.9 724.7%   
Net profit margin %13.92.5 562.0%  
BALANCE SHEET DATA
Current assets Rs m9,52224,836 38.3%   
Current liabilities Rs m3,29618,993 17.4%   
Net working cap to sales %110.420.6 536.5%  
Current ratio x2.91.3 220.9%  
Inventory Days Days3771 51.6%  
Debtors Days Days28113 25.1%  
Net fixed assets Rs m4634,289 0.1%   
Share capital Rs m123895 13.8%   
"Free" reserves Rs m7,21323,651 30.5%   
Net worth Rs m7,33624,546 29.9%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m11,10565,437 17.0%  
Interest coverage x29.51.7 1,719.2%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.4 117.0%   
Return on assets %7.64.1 185.5%  
Return on equity %10.72.9 373.4%  
Return on capital %22.26.9 322.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6115,697 0.4%   
Fx outflow Rs m3,630735 493.6%   
Net fx Rs m-3,57014,962 -23.9%   
CASH FLOW
From Operations Rs m1,6101,871 86.1%  
From Investments Rs m6875,826 11.8%  
From Financial Activity Rs m-2,677-10,157 26.4%  
Net Cashflow Rs m-380-2,615 14.5%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 37.8 5.3%  
FIIs % 1.6 8.6 18.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 25.9 83.0%  
Shareholders   41,647 56,241 74.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   AUROBINDO PHARMA  PROCTER & GAMBLE HEALTH  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 19, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS